EZH2 mutations
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-16 — Allogeneic Transplantation in the Rare Disease Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia: Age and Disease Burden Determine Outcome.: In the largest reported allo-HCT cohort (n=85) of MDS/MPN with neutrophilia, EZH2 mutations independently predicted higher relapse and inferior relapse-free survival after transplant, identifying EZH2 as an adverse molecular marker in the transplant setting for this rare overlap syndrome. (novelty: 3)
Open questions
Related
Contributing findings
Allogeneic Transplantation in the Rare Disease Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Neutrophilia: Age and Disease Burden Determine Outcome.
16-jun-2026
novelty 3
per-area 3
introduces